Patents by Inventor Mark R. Krystal

Mark R. Krystal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Polypeptides targeting HIV fusion
    Patent number: 11155602
    Abstract: The invention is directed to polypeptides comprising a CD4 binding moiety, a gp41 binding moiety, a HIV fusion peptide inhibitor moiety and combinations thereof. More specifically, the present invention relates to polypeptides comprising a fibronectin-based scaffold domain protein that binds CD4, a fibronectin-based scaffold domain protein that binds the N17 domain of gp41, and a HIV fusion peptide inhibitor or combinations thereof. The invention also relates to the use of the innovative proteins in therapeutic applications to treat HIV.
    Type: Grant
    Filed: August 7, 2019
    Date of Patent: October 26, 2021
    Inventors: Mark R. Krystal, David L. Wensel, Jonathan Davis
  • Polypeptides Targeting HIV Fusion
    Publication number: 20190359688
    Abstract: The invention is directed to polypeptides comprising a CD4 binding moiety, a gp41 binding moiety, a HIV fusion peptide inhibitor moiety and combinations thereof. More specifically, the present invention relates to polypeptides comprising a fibronectin-based scaffold domain protein that binds CD4, a fibronectin-based scaffold domain protein that binds the N17 domain of gp41, and a HIV fusion peptide inhibitor or combinations thereof. The invention also relates to the use of the innovative proteins in therapeutic applications to treat HIV.
    Type: Application
    Filed: August 7, 2019
    Publication date: November 28, 2019
    Inventors: Mark R. KRYSTAL, David L. Wensel, Jonathan Davis
  • Polypeptides targeting HIV fusion
    Patent number: 10407490
    Abstract: The invention is directed to polypeptides comprising a CD4 binding moiety, a gp41 binding moiety, a HIV fusion peptide inhibitor moiety and combinations thereof. More specifically, the present invention relates to polypeptides comprising a fibronectin-based scaffold domain protein that binds CD4, a fibronectin-based scaffold domain protein that binds the N17 domain of gp41, and a HIV fusion peptide inhibitor or combinations thereof. The invention also relates to the use of the innovative proteins in therapeutic applications to treat HIV.
    Type: Grant
    Filed: April 14, 2016
    Date of Patent: September 10, 2019
    Assignee: VIIV HEALTHCARE UK (NO.5) LIMITED
    Inventors: Mark R. Krystal, David L. Wensel, Jonathan Davis
  • FOSTEMSAVIR FOR USE IN HEAVILY TREATMENT-EXPERIENCED HIV-1 INFECTED INDIVIDUALS
    Publication number: 20190030025
    Abstract: A method of attaining virologic suppression in a heavily treatment-experienced (HTE) individual infected with the HIV-1 virus involves administering to the individual a treatment regimen comprising the drug fostemsavir together with an optimized background therapy (OBT). This treatment regimen should maintain virologic suppression to a plasma HIV-1 RNA level of less than 200 copies (c)/mL for an extended period.
    Type: Application
    Filed: February 2, 2017
    Publication date: January 31, 2019
    Inventors: Dennis Michael GRASELA, George HANNA, Mark R. KRYSTAL, Max LATAILLADE
  • Polypeptides Targeting HIV Fusion
    Publication number: 20180111980
    Abstract: The invention is directed to polypeptides comprising a CD4 binding moiety, a gp41 binding moiety, a HIV fusion peptide inhibitor moiety and combinations thereof. More specifically, the present invention relates to polypeptides comprising a fibronectin-based scaffold domain protein that binds CD4, a fibronectin-based scaffold domain protein that binds the N17 domain of gp41, and a HIV fusion peptide inhibitor or combinations thereof. The invention also relates to the use of the innovative proteins in therapeutic applications to treat HIV.
    Type: Application
    Filed: April 14, 2016
    Publication date: April 26, 2018
    Inventors: Mark R. KRYSTAL, David L. WENSEL, Jonathan DAVIS
  • N-[[4-fluoro-2-(5-methy-1H-1,2,4-triazol-1-yl)phenyl]methyl]-4-,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide as an HIV integrase inhibitor
    Patent number: 7511037
    Abstract: The invention encompasses a series of bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.
    Type: Grant
    Filed: August 16, 2006
    Date of Patent: March 31, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: B. Narasimhulu Naidu, Jacques Banville, Francis Beaulieu, Timothy P. Connolly, Mark R. Krystal, John D. Matiskella, Carl Ouellet, Serge Plamondon, Roger Remillard, Margaret E. Sorenson, Yasutsugu Ueda, Michael A. Walker
  • Bicyclic heterocycles as HIV integrase inhibitors
    Patent number: 7176196
    Abstract: The invention encompasses a series cyclic bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.
    Type: Grant
    Filed: May 11, 2005
    Date of Patent: February 13, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: B. Narasimhulu Naidu, Jacques Banville, Francis Beaulieu, Timothy P. Connolly, Mark R. Krystal, John D. Matiskella, Carl Ouellet, Serge Plamondon, Roger Remillard, Margaret E. Sorenson, Yasutsugu Ueda, Michael A. Walker
  • Bicyclic heterocycles as HIV integrase inhibitors
    Patent number: 7157447
    Abstract: The invention encompasses a series bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS.
    Type: Grant
    Filed: November 29, 2005
    Date of Patent: January 2, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: B. Narasimhulu Naidu, Jacques Banville, Francis Beaulieu, Timothy P. Connolly, Mark R. Krystal, John D. Matiskella, Carl Ouellet, Serge Plamondon, Roger Remillard, Margaret E. Sorenson, Yasutsugu Ueda, Michael A. Walker
  • Substituted benzimidazole antiviral agents
    Patent number: 7030140
    Abstract: The present invention concerns antiviral compounds, their compositions, and use in the treatment of viral infections. More particularly, the invention provides benzimidazole derivatives for the treatment of respiratory syncytial virus infection.
    Type: Grant
    Filed: September 3, 2004
    Date of Patent: April 18, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kuo-Long Yu, Rita Lee Civiello, Mark R. Krystal, Kathleen F. Kadow, Nicholas A. Meanwell
  • Substituted benzimidazole antiviral agents
    Patent number: 6908936
    Abstract: The present invention concerns antiviral compounds, their compositions, and use in the treatment of viral infections. More particularly, the invention provides benzimidazole derivatives for the treatment of respiratory syncytial virus infection.
    Type: Grant
    Filed: November 7, 2002
    Date of Patent: June 21, 2005
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kuo-Long Yu, Rita Lee Civiello, Mark R. Krystal, Kathleen F. Kadow, Nicholas A. Meanwell
  • Substituted benzimidazole antiviral agents
    Publication number: 20030139450
    Abstract: The present invention concerns antiviral compounds, their compositions, and use in the treatment of viral infections. More particularly, the invention provides benzimidazole derivatives for the treatment of respiratory syncytial virus infection.
    Type: Application
    Filed: November 7, 2002
    Publication date: July 24, 2003
    Inventors: Kuo-Long Yu, Rita Lee Civiello, Mark R. Krystal, Kathleen F. Kadow, Nicholas A. Meanwell